09.01.11 |
Oncology Drug Development and Personalized Medicine: Clinical Evaluation of Combinations of Novel Targeted Drugs and Co-development of Companion Diagnostics |
07.07.11 |
Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer |
04.12.11 |
Approval of AstraZeneca’s Multi-targeted Anticancer Drug Vandetanib for the Treatment of Advanced Medulllary Thyroid Cancer Broadens the Application of Inhibitors of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer |
10.13.10 |
Novel Immunotherapy/Therapeutic Vaccines in Malignant Melanoma-Global Development Status |
02.23.09 |
New Medicine's Oncology KnowledgeBASE (nm|OK)-A Comprehensive Resource in the Diagnosis/Prognosis and Drug Development in Cancer
|
06.11.08 |
Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success |
03.26.08 |
Diagnostics, Theragnostics, Prognostics, Pharmacogenomics and Biomarkers in Oncology
Numerous Commercial and Academic Groups are Developing Products/Technologies that Will Play a Critical Role in Clinical Trial Design and Patient Selection and Treatment Assessment, and May Determine the Future Success of Anticancer Drugs |
02.19.08 |
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics |
11.27.07 |
Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of nearly $5 billion in the First Nine Months of 2007 |
09.18.07 |
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development |
07.17.07 |
Oncology Drug Development-Mid-Year 2007 Update |
05.29.07 |
Oncology Drug Development Update - Targeted Drugs from the 2007 Meeting of the American Association of Cancer Research (AACR) |
04.03.07 |
Oncology Drug Development Update - EGFr-Targeted Drugs: Vectibix Setback, EGFr Testing |
03.27.07 |
Oncology Drug Development Information Resources |
01.09.07 |
Oncology Drug Development Information Resources |
10.09.06 |
Oncology Drug Development Update - Targeting the Epidermal Growth Factor Receptor (EGFr) Signal Transduction Pathway |
07.12.06 |
Oncology Drug Development Update - Over 600 Novel Anticancer Agents in Development were Added in New Medicine's Oncology KnowledgeBASE (nm|OK) in the first 6 months of 2006, Including Over 190 Agents in Clinical Development Targeting over 154 Distinct Molecular Markers |
02.07.06 |
Oncology Drug Development Update - Monotherapy Phase I Clinical Trials of Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapeutics/Vaccines |
11.30.05 |
Oncology Drug Development Update - Monotherapy Phase I Clinical Trials of Novel Drugs/Formulations-Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapy/Vaccines |
10.10.05 |
Oncology Drug Development Update
|
07.19.05 |
Oncology Drug Development: the c-SRC Signaling Pathway |
05.03.05 |
Oncology Drug Development Update - Over 545 New Drugs were Added in the First Four Months of 2005, from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK) |
04.26.05 |
Update on Pancreatic Cancer - Epidemiology · Molecular Markers · Prognosis, Diagnosis and Disease Monitoring · State-of-the-Art Treatments · Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents, and Immunotherapy/Vaccines |
04.05.05 |
Oncology Drug Development Update - The Records of Numerous Novel Spindle Poisons, Including Taxanes, Epothilones and Other Antimitotics, have been Updated in New Medicine's Oncology KnowledgeBASE (nm|OK) |
02.16.05 |
Oncology Drug Development Update - Over 142 Records of Novel Drugs Were Added in January 2005 from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK) |
07.08.04 |
Oncology Drug Development Update June 2004 |
09.16.03 |
Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials |
04.30.03 |
Anticancer Agents From Antibiotic Sources - New Antibiotics, Analogs and
Derivatives, and Targeted Cytotoxics - a Report From New Medicine |
11.05.02 |
Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials |
9.18.02 |
Update on Spindle Poisons-Taxanes, Vinca Alkaloids and Novel Anticancer Drugs Acting by Disrupting the Cytoskeleton of Tumor Cells |
8.07.02 |
Oncology Drug Development Update 2002 |
6.26.02 |
Numerous Novel Anticancer Agents Are in Early-Stage of Clinical Development |
6.05.02 |
New Strategies Regarding Combination Therapies, Target Validation and Chemoprevention Taking Center Stage in Cancer Drug Development |
3.12.02 |
Future Oncology Issues a Comprehensive Report on Clinical and Market Developments in the Taxane Group of Spindle Poisons |
11.05.01 |
New Medicine posted estimates of global markets for anticancer agents and adjuncts on its subscription-based oncologyknowledgebase.net website |
7.10.01 |
Over 300 Clinical Trials Involving More Than 100 Anticancer Agents Acting By Regulatory Rather Than Cytotoxic Mechanisms Have Been Initiated According to New Medicine's Oncology KnowledgeBASE (nm/OK) Commercialization of These Agents as Monotherapies and/or Combination Therapies Will Revolutionize the Way Cancer is Treated |
3.20.01 |
Over 547 Anticancer Drugs Based on Novel Mechanisms Are in Development With Many in Late-Stage Clinical Trials, According to Oncology KnowledgeBASE
Commercialization of These Agents Will Revolutionize the Way Cancer Is Treated |
11.08.00 |
Over 1,500 Anticancer Agents are in Active Development, With 522 in Clinical Trials, According to Web-Based New Medicine's Oncology KnowledgeBASE (nm/OK) |
9.27.00 |
Future Oncology Publishes A Comprehensive Review of Lung Cancer Comprising WorldWide Epidemiology, Current Treatment Approaches, Novel Agents In Development, And Market Opportunities |
12.07.99 |
Future Oncology Publishes A Comprehensive Review Of Markets Of Oncology Drugs |
8.03.99 |
New Medicine Issues A Comprehensive Report On Worldwide Product Development And Market Opportunities In The Management Of Moderate-To-Severe Pain With Special Emphasis On Cancer-Related Pain |
6.01.99 |
Demo of New Medicine’s Comprehensive Oncology Knowledgebase Now On The Company’s Web Site |
10.07.98 |
Future Oncology Publishes A Comprehensive Review Of Prostate Cancer And Identifies Over 180 Separate Products In Development To Treat This Disease |
